Literature DB >> 8702627

Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas.

B Li1, B Ouyang, H Pan, P T Reissmann, D J Slamon, R Arceci, L Lu, W Dai.   

Abstract

We have cloned and characterized a putative protein serine/threonine kinase termed prk through a combination of polymerase chain reaction and conventional cDNA library screening approaches. There are apparently two distinct domains within prk protein deduced from its nucleotide sequences. The amino-terminal portion has the feature of the catalytic domain of a serine/threonine kinase and shows strong homology to mouse fnk and other polo family kinases including mouse snk, human and murine plk, Drosophila polo, and yeast Cdc5. The carboxyl-terminal portion, presumably the regulatory domain, shares extensive homology to mouse fnk. Northern blotting analyses reveal that prk expression is restricted to a very limited number of tissues with placenta, ovaries, and lung containing detectable amounts of prk mRNA. prk mRNA expression is also detected at a low level in the megakaryocytic cell line Dami, MO7e, and three brain glioma cell lines. In addition, refeeding of serum-deprived MO7e, Dami, and K562 cells of hematopoietic origin and GMOO637D of lung fibroblasts rapidly activates prk mRNA expression with its peak induction around 2 h after serum addition. prk gene activation by the serum requires no new protein synthesis. The recombinant cytokines such as interleukin-3 and thrombopoietin also activate prk mRNA expression in MO7e cells. Furthermore, a survey of RNAs isolated from the tumor and the uninvolved tissues from 18 lung cancer patients reveals that prk mRNA expression is significantly down-regulated in tumor tissues. Southern blotting analysis indicates that the prk gene is present in a single copy in the genome of tumors and normal cells. Taken together, these results suggest that prk expression may be restricted to proliferating cells and involved in the regulation of cell cycle progression. The molecular cloning of prk cDNA will facilitate the study of its biological role as well as its potential role in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702627     DOI: 10.1074/jbc.271.32.19402

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

2.  Essential function of the polo box of Cdc5 in subcellular localization and induction of cytokinetic structures.

Authors:  S Song; T Z Grenfell; S Garfield; R L Erikson; K S Lee
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  Hyperosmotic stress-induced ATF-2 activation through Polo-like kinase 3 in human corneal epithelial cells.

Authors:  Ling Wang; Reid Payton; Wei Dai; Luo Lu
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

4.  Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells.

Authors:  Meghna U Naik; Ngoc T Pham; Kristin Beebe; Wei Dai; Ulhas P Naik
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 5.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

6.  Plk phosphorylation regulates the microtubule-stabilizing protein TCTP.

Authors:  Frederic R Yarm
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

Review 7.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Stimulation of polo-like kinase 3 mRNA decay by tristetraprolin.

Authors:  Thierry J Horner; Wi S Lai; Deborah J Stumpo; Perry J Blackshear
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

9.  Phosphorylation of synucleins by members of the Polo-like kinase family.

Authors:  Martial K Mbefo; Katerina E Paleologou; Ahmed Boucharaba; Abid Oueslati; Heinrich Schell; Margot Fournier; Diana Olschewski; Guowei Yin; Markus Zweckstetter; Eliezer Masliah; Philipp J Kahle; Harald Hirling; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

Review 10.  Polo-like kinase 3, hypoxic responses, and tumorigenesis.

Authors:  Dazhong Xu; Wei Dai; Cen Li
Journal:  Cell Cycle       Date:  2017-09-21       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.